Population pharmacokinetics of vancomycin in Chinese infants

被引:9
|
作者
Sheng, Xiao-yan [1 ]
Chen, Chao-yang [1 ]
Ma, Ling-yue [1 ]
Liu, Ya-ou [1 ]
Zhou, Ying [1 ]
Cui, Yi-min [1 ]
机构
[1] Peking Univ, Hosp 1, Dept Pharm, 6 Da Hong Luo Chang St, Beijing 100034, Peoples R China
关键词
vancomycin; population pharmacokinetics; infants; Chinese; individualized treatment; DOSING OPTIMIZATION; CHILDREN; PREDICTION; MODEL;
D O I
10.5414/CP202827
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To determine the pharmacokinetics (PK) of vancomycin in Chinese infant patients using a population pharmacokinetic (PKK) approach in order to provide support for individualized vancomycin therapy. Method: The data included 72 sets of steady-state peak and trough serum concentrations from 61 infants (0 - 1 years). PPK analysis was performed using the non-linear mixed-effects modeling software. Inter- and intraindividual variability was estimated for the clearance and distribution volume of vancomycin. The potential effects of patient sex, postnatal age, postconceptional age, height, weight, body surface area, body mass index, alanine aminotransferase, aspartate aminotransferase, total protein, albumin, white blood cell count, serum creatinine, and concomitant medications on vancomycin PKs were explored. Results: A one-compartment linear model with first-order elimination was used to describe the data. Weight and postnatal age had a significant influence on vancomycin clearance. The typical population parameter estimates of clearance and distribution volume were 0.46 L/h and 4.45 L, respectively. Goodness-of-fit plots and bootstrap outcomes confirmed the relatively good stability and prediction capability of the model. Conclusion: This study initially established a vancomycin PPK model to estimate individual PK parameters in Chinese infant patients.
引用
收藏
页码:558 / 566
页数:9
相关论文
共 50 条
  • [31] Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children
    Keith A. Rodvold
    Julie A. Everett
    Randy D. Pryka
    Donna M. Kraus
    Clinical Pharmacokinetics, 1997, 33 : 32 - 51
  • [32] PHARMACOKINETICS BASIS FOR VANCOMYCIN DOSING IN PREMATURE-INFANTS
    REED, M
    HUANG, M
    WEINER, J
    HULMAN, S
    KLIEGMAN, R
    BLUMER, J
    ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1986, 59 : 186 - 186
  • [33] Population Pharmacokinetics of Vancomycin in Postoperative Neurosurgical Patients
    Li, Xingang
    Wu, Yuanxing
    Sun, Shusen
    Mei, Shenghui
    Wang, Jiaqing
    Wang, Qiang
    Zhao, Zhigang
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (11) : 3960 - 3967
  • [34] Population pharmacokinetics of vancomycin in Japanese pediatric patients
    Yasuhara, M
    Iga, T
    Zenda, H
    Okumura, K
    Oguma, T
    Yano, Y
    Hori, R
    THERAPEUTIC DRUG MONITORING, 1998, 20 (06) : 612 - 618
  • [35] Population pharmacokinetics and dose optimization of vancomycin in neonates
    Soon Min Lee
    Seungwon Yang
    Soyoung Kang
    Min Jung Chang
    Scientific Reports, 11
  • [36] Population pharmacokinetics and dose optimization of vancomycin in neonates
    Lee, Soon Min
    Yang, Seungwon
    Kang, Soyoung
    Chang, Min Jung
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [37] Population pharmacokinetics of vancomycin in Japanese adult patients
    Yasuhara, M
    Iga, T
    Zenda, H
    Okumura, K
    Oguma, T
    Yano, Y
    Hori, R
    THERAPEUTIC DRUG MONITORING, 1998, 20 (02) : 139 - 148
  • [38] Population pharmacokinetics of arbekacin, vancomycin, and panipenem in Neonates
    Kimura, T
    Sunakawa, K
    Matsuura, N
    Kubo, H
    Shimada, S
    Yago, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) : 1159 - 1167
  • [39] Population Pharmacokinetics of Vancomycin in Paediatrics - A Systematic Review
    Chung, E.
    Sen, J.
    Patel, P.
    Seto, W.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2021, 74 (02): : 178 - 178
  • [40] Population pharmacokinetics of intraventricular vancomycin in neonatal ventriculitis
    Parasuraman, J. M.
    Kloprogge, F.
    Standing, J. F.
    Albur, M.
    Heep, A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) : 1641 - 1642